Lansoprazole is a proton pump inhibitor used to help gastrointestinal ulcers heal, to treat symptoms of gastroesophageal reflux disease (GERD), to eradicate Helicobacter pylori, and to treat hypersecretory conditions such as Zollinger-Ellison Syndrome. Lansoprazole marketed under the brand Prevacid, is a proton pump inhibitor (PPI) and is structurally classified as a substituted benzimidazole.
- Mechanism
- Curator reviewed · 4 references
As a PPI, lansoprazole is a prodrug and requires protonation via an acidic environment to become activated. Once protonated, lansoprazole is able to react with cysteine residues, specifically Cys813 and Cys321, on parietal H+,K+-ATPase resulting in stable disulfides. PPI's in general are able to provide prolonged inhibition of acid secretion due to their ability to bind covalently to their targets.
- Primary indication
- Lansoprazole is used to reduce gastric acid secretion and is approved for short term treatment of active gastric ulcers, active duodenal ulcers, erosive reflux oesophagitis, symptomatic gastroesophageal reflux disease, and non-steroidal anti-inflammatory drug (NSAID) induced...Curator reviewed · 15 structured indications
- Formula / weight
- C16H14F3N3O2S · 369.361 g/mol (avg)
- First approval
- Canada, 2008 · United States, 1995
- Also known as
- Lanzoprazole
- Code names
- A-65006 · AG-1749
- Brand names
Resolves to
MJIHNNLFOKEZEW-UHFFFAOYSA-NSMILESCC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1What you can answer from here — as of September 23, 2026
Which drugs share a target with Lansoprazole, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account